Cytek Biosciences, Inc.

NASDAQ:CTKB

5.29 (USD) • At close September 19, 2024
Overview | Financials

Numbers are in millions (except for per share data and ratios) USD.

2024 Q22024 Q12023 Q42023 Q32023 Q22023 Q12022 Q42022 Q32022 Q22022 Q12021 Q42021 Q32021 Q22021 Q12020 Q42020 Q32020 Q22020 Q1
Revenue 46.61744.8658.2334849.69337.08848.33640.47740.15935.06438.89434.37630.40824.27230.61925.09619.13617.988
Cost of Revenue 21.18121.84725.18520.82221.53116.0518.96213.61515.59814.88715.25812.9910.6639.78611.179.4810.8669.613
Gross Profit 25.43623.01333.04827.17828.16221.03829.37426.86224.56120.17723.63621.38619.74514.48619.44915.6168.278.375
Gross Profit Ratio 0.5460.5130.5680.5660.5670.5670.6080.6640.6120.5750.6080.6220.6490.5970.6350.6220.4320.466
Reseach & Development Expenses 10.0019.79610.86911.17112.1369.9749.7478.658.4368.0257.0766.0786.1945.0944.3853.3762.9163.016
General & Administrative Expenses 11.69411.40810.75510.35110.78612.08110.5148.0428.5857.5496.9295.9054.1643.9832.6281.6912.5132.538
Selling & Marketing Expenses 12.26812.54311.56112.07614.36711.1459.0298.818.4316.968.3046.3315.5764.2774.563.8383.0593.531
SG&A 23.96223.95122.31622.42725.15323.22619.54316.85217.01614.50915.23312.2369.748.267.1885.5295.5726.069
Other Expenses 0.0590.8233.1941.2081.741.6522.091-0.445-0.254-0.374-0.399-0.393-0.12-0.6150.4510.1850.395-0.037
Operating Expenses 33.96333.74733.18533.59837.28933.229.2925.50225.45222.53422.30918.31415.93413.35411.5738.9058.4889.085
Operating Income -8.527-10.734-0.137-6.42-9.127-12.1622.9372.499-0.891-2.3571.3273.0723.8111.1327.8766.711-0.218-0.71
Operating Income Ratio -0.183-0.239-0.002-0.134-0.184-0.3280.0610.062-0.022-0.0670.0340.0890.1250.0470.2570.267-0.011-0.039
Total Other Income Expenses Net 1.3411.7414.2481.2081.743.1221.177-0.649-0.254-0.946-0.399-0.393-0.12-0.6150.4510.1850.395-0.037
Income Before Tax -7.186-8.9934.111-4.185-6.595-9.044.1141.85-1.401-3.3030.4542.253.2670.1528.0026.8970.192-0.661
Income Before Tax Ratio -0.154-0.20.071-0.087-0.133-0.2440.0850.046-0.035-0.0940.0120.0650.1070.0060.2610.2750.01-0.037
Income Tax Expense 3.248-2.824-1.3922.271-2.207-2.2330.3960.224-0.699-1.1450.2030.6550.5970.052.4030.357-7.9190.178
Net Income -10.434-6.1695.503-6.456-4.388-6.8073.5291.666-0.598-2.1580.2251.5952.670.1025.5996.548.111-0.839
Net Income Ratio -0.224-0.1380.094-0.135-0.088-0.1840.0730.041-0.015-0.0620.0060.0460.0880.0040.1830.2610.424-0.047
EPS -0.079-0.0470.042-0.047-0.032-0.050.0260.012-0.004-0.0160.0020.0150.020.0010.0470.210.26-0.007
EPS Diluted -0.079-0.0470.042-0.047-0.032-0.050.0260.012-0.004-0.0160.0020.0140.020.0010.0460.180.23-0.007
EBITDA -6.047-8.2742.288-3.59-3.741-8.3674.8013.270.8-1.2430.9462.6913.70.6948.497.0780.354-0.556
EBITDA Ratio -0.13-0.1840.039-0.075-0.075-0.2260.0990.0810.02-0.0350.0240.0780.1220.0290.2770.2820.018-0.031